GSK invests $300,000 to help launch the Pharmacy Innovation in Immunization Research Collaborative (PIIRC) at the University of Waterloo School of Pharmacy Français
PIIRC serves as a catalyst for innovation by supporting interdisciplinary research and real-world evidence generation focused on improving vaccine access, delivery and education.
MISSISSAUGA, ON, June 6, 2025 /CNW/ - GSK is proud to announce a $300,000 investment in the Pharmacy Innovation in Immunization Research Collaborative (PIIRC), a new national initiative led by the School of Pharmacy at the University of Waterloo. This groundbreaking initiative reflects a shared commitment to expanding the role of pharmacy in Canada's immunization landscape and improving equitable access to vaccines across the country.
Immunization has never been more critical. The COVID-19 pandemic underscored the life-saving power of vaccines and demonstrated the essential role that pharmacists and pharmacies play in public health. Pharmacy teams have administered more than 20 million COVID-19 vaccines in Canada alone. Yet, there remains untapped potential to leverage the country's 11,000+ pharmacies as accessible, community-based hubs for broader immunization services. PIIRC aims to close that gap.
Launched by the largest clinical pharmacy practice research group in Canada, PIIRC serves as a catalyst for innovation by supporting interdisciplinary research and real-world evidence generation focused on improving vaccine access, delivery and education. The initiative brings together researchers from the University of Waterloo, national and international collaborators, policymakers and stakeholders across healthcare and industry to advance pharmacy-based immunization strategies.
"As a global leader in vaccines, we believe in harnessing science and partnerships to tackle the world's most pressing health challenges," said Michelle Horn, Country Medical Director, GSK Canada. "Through our founding partnership with PIIRC, we are investing not only in research, but in the future of vaccine delivery in Canada—one that is more accessible, equitable, and community-centred."
Transforming Immunization Through Pharmacy Innovation
The objective of PIIRC is to re-imagine the role of pharmacy in immunization—from vaccine administration to health education, monitoring, and system design. Areas of research will include:
Expanding the role of pharmacists and pharmacy technicians as vaccine educators, facilitators, and immunizers
Overcoming barriers to access, especially among rural residents, older adults, immunocompromised individuals, and other underserved populations
Leveraging digital health tools and technology to support clinical decision-making and personalized outreach
Countering vaccine misinformation through evidence-based communication strategies and resources for healthcare providers
Conducting economic analyses to examine the cost-effectiveness and public health value of pharmacy-based vaccine services
Implementing science methodologies to ensure successful and scalable solutions across regions and populations
This work will be supported by the School's extensive expertise in pharmacy practice research, health systems design, health economics, public policy, behavioural science, and communication strategies.
"As a leader in clinical pharmacy practice research and community pharmacy innovation, the University of Waterloo's School of Pharmacy continues to push boundaries," said Andrea Edginton, Hallman Director, School of Pharmacy at the University of Waterloo. "PIIRC is a natural evolution of our work in immunization, and GSK's partnership will accelerate breakthroughs that improve public health both in Canada and globally."
Impact Beyond the Lab
In addition to funding innovative research, GSK's investment will also:
Provide funding to support new interdisciplinary projects with direct policy and practice implications
Train the next generation of immunization researchers, including PharmD students, graduate students and postdoctoral fellows
Facilitate enhanced access to real-world pharmacy data to monitor vaccine uptake and identify areas for intervention
Establish a network of community pharmacies engaged in research, data collection and pilot projects
Enable regular knowledge translation activities to ensure research is informed by and disseminated to industry, government and community stakeholders
Support the creation of an Advisory Board that includes voices from pharmaceutical and insurance companies, regulators, pharmacy associations and the public
Strategic Alignment with Public Health and Policy
This investment directly supports the Ontario Life Sciences Strategy by demonstrating private sector leadership in supporting community-based immunization services. By investing in evidence that shows how pharmacy can help achieve broader public health goals—including for future vaccine program rollouts such as RSV—GSK is playing a critical role in advancing both healthcare outcomes and policy development.
"Our support for PIIRC is not just about generating data; it's about making a meaningful contribution to the future of healthcare," added Michelle Horn, Country Medical Director, GSK Canada. "We're proud to stand alongside the University of Waterloo School of Pharmacy in driving innovative, patient-centred immunization strategies that reflect our mission to get ahead of disease together and our commitment to doing what's right for communities and for public health."
Why Waterloo and Why Now?
The University of Waterloo's collaborative ethos, track record of external partnerships and commitment to impact make it an ideal home for PIIRC. The University creates substantial opportunities for high-impact partnerships that bridge the gap between research and application.
PIIRC helps shape policy and guides decision-making with timely, actionable evidence that reflects the realities of patients, pharmacists and public health professionals. GSK's early and decisive investment solidifies its reputation as a forward-thinking leader in the pharmacy space and a partner of choice in advancing vaccine innovation.
About the University of Waterloo School of Pharmacy
The School of Pharmacy at the University of Waterloo is home to Canada's largest clinical pharmacy practice research group and is at the forefront of pharmacy innovation. Through interdisciplinary research and industry collaboration, the School is advancing pharmacy's role in improving health systems and patient outcomes.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. Find out more at www.ca.gsk.com/en-ca.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025.
SOURCE GlaxoSmithKline Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
3 hours ago
- Toronto Star
Need for regulation is urgent as AI chatbots are being rolled out to support mental health
We are told that we are experiencing a global mental health crisis. According to the World Health Organization (WHO), some common conditions, such as anxiety and depression, increased by 25 per cent in the first year of the COVID-19 pandemic, adding to the estimated nearly one billion people already living with mental disorders worldwide. The WHO reports that globally, one in seven 10-to-19-year-olds suffer from a mental health disorder, and suicide is the third-most common cause of death in 15-to-29-year-olds. Opinion articles are based on the author's interpretations and judgments of facts, data and events. More details
Cision Canada
6 hours ago
- Cision Canada
ESHRE 41st Annual Meeting: Older paternal age linked to higher miscarriage risk and lower live birth rates in donor egg IVF cycles
A new international study presented today at the 41 st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) reveals that IVF cycles involving male partners over the age of 45 carry significantly increased miscarriage risks and lower live birth rates – even when young donor eggs are used. PARIS, June 29, 2025 /CNW/ -- By isolating paternal age from female reproductive factors through the exclusive use of donor eggs from young women, the study provides robust evidence that male age plays a critical role in reproductive success, challenging the common assumption that sperm age has little impact once fertilisation occurs. The retrospective study analysed 1,712 first oocyte donation cycles conducted between 2019 and 2023 across six IVF centres in Italy and Spain. All cycles used fresh donor oocytes and frozen sperm from male partners, with only the first single blastocyst transfer included. Female recipients had a mean age of 43.3 years. Participants were divided into two groups: men aged 45 or younger (n=1,066) and those over 45 (n=646). While fertilisation rates and embryo development were comparable between groups, significant differences emerged in clinical outcomes. Miscarriage rates were notably higher among couples where the male partner was over 45, reaching 23.8% compared to 16.3% in the younger paternal age group. Similarly, live birth rates were significantly lower in the older paternal age group, at 35.1% versus 41% for men aged 45 or younger. Discussing the findings, Dr. Maria Cristina Guglielmo, Embryologist at Eugin Italy, said, "Traditionally, maternal age has been the central focus in reproductive medicine, but our results show that the age of the male partner also plays a crucial and independent role. Even when using eggs from young, healthy donors and transferring only a single, high-quality embryo, we observed poorer outcomes in men over 45." She also emphasised the importance of examining how paternal age affects the health of offspring. "There is growing evidence linking advanced paternal age to an increased risk of neurodevelopment disorders in children. Our future work will investigate the long-term health and developmental outcomes of children conceived through donor egg cycles with older fathers, where maternal factors are minimised, to isolate paternal effects more clearly." The study abstract will be published today in Human Reproduction, one of the world's leading reproductive medicine journals.
Cision Canada
a day ago
- Cision Canada
ESOT Congress 2025: Scientists create functional human islets in 3D printing breakthrough for type 1 diabetes treatment
LONDON, /CNW/ -- A team of international scientists has made a major leap forward in diabetes research by successfully 3D printing functional human islets using a novel bioink. Presented today at the ESOT Congress 2025, the new technology could pave the way for more effective and less invasive treatment for people living with type 1 diabetes. The breakthrough involved printing human islets – the insulin-producing clusters of cells in the pancreas – using a customised bioink made from alginate and decellularised human pancreatic tissue. This approach produced durable, high-density islet structures that remained alive and functional for up to three weeks, maintaining strong insulin responses to glucose and showing real potential for future clinical use. Traditional islet transplants are typically infused into the liver, a process that can result in significant loss of cells and limited long-term success. In contrast, the 3D-printed islets were designed to be implanted just under the skin, a simple procedure requiring only local anaesthesia and a small incision. This minimally invasive approach could offer a safer and more comfortable option for patients. "Our goal was to recreate the natural environment of the pancreas so that transplanted cells would survive and function better," explained lead author Dr. Quentin Perrier. "We used a special bioink that mimics the support structure of the pancreas, giving islets the oxygen and nutrients they need to thrive." The bioprinted islets stayed alive and healthy, with over 90% cell survival. They responded better to glucose than standard islet preparations, releasing more insulin when it was needed. By day 21, the islets showed a stronger ability to sense and react to blood sugar levels – an important sign that they could work well after being implanted. The constructs maintained their structure without clumping or breaking down, overcoming a common hurdle in earlier approaches. Additionally, the 3D-printed structures featured a porous architecture that enhanced the flow of oxygen and nutrients to the embedded islets. This design helped maintain cell health and promoted vascularisation, both of which are critical for long-term survival and function after transplantation. "This is one of the first studies to use real human islets instead of animal cells in bioprinting, and the results are incredibly promising," noted Dr. Perrier. "We're getting closer to creating an off-the-shelf treatment for diabetes that could one day eliminate the need for insulin injections."
